Q-omics provides the consensus-scored ZNF575 profile across patient tissues and cancer cell-line models. ZNF575 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF575 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ZNF575 RNA expression shows 17,299 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where ZNF575 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF575 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF575 survival associations across molecular data types. ZNF575 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF575 RNA expression–survival associations across cancer types. High ZNF575 expression shows unfavorable associations in LGG and READ, but favorable associations in HNSC, PCPG, UVM and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF575 RNA expression.
This table summarizes ZNF575 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF575. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF575 shows lower tumor expression in COAD, KICH, LUAD, UCEC and BLCA and higher tumor expression in LIHC. The COAD box plot shows higher ZNF575 RNA expression in normal versus tumor tissue (log2 FC = −1.702, t-test p < 0.001).
This table shows molecular features associated with ZNF575 in patient tissues and cancer cell lines. In patient samples, ZNF575 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF575 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
